NeoPharm CO., LTD. (KOSDAQ:092730)
South Korea
· Delayed Price · Currency is KRW 21,650
+450 (2.12%)
Apr 29, 2026, 10:50 AM KST
NeoPharm CO., LTD. Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 132,184 | 119,014 | 97,105 | 85,033 | 87,931 | Upgrade
|
| Other Revenue | - | - | - | -0 | - | Upgrade
|
| Revenue | 132,184 | 119,014 | 97,105 | 85,033 | 87,931 | Upgrade
|
| Revenue Growth (YoY) | 11.07% | 22.56% | 14.20% | -3.29% | 7.72% | Upgrade
|
| Cost of Revenue | 45,786 | 44,987 | 31,720 | 26,653 | 25,544 | Upgrade
|
| Gross Profit | 86,398 | 74,027 | 65,385 | 58,380 | 62,386 | Upgrade
|
| Selling, General & Admin | 52,602 | 44,259 | 36,276 | 32,984 | 36,022 | Upgrade
|
| Research & Development | 3,335 | 3,407 | 2,647 | 2,854 | 2,935 | Upgrade
|
| Amortization of Goodwill & Intangibles | 258.4 | 491.92 | 414.51 | 416.67 | 420.2 | Upgrade
|
| Operating Expenses | 57,624 | 49,374 | 40,078 | 36,941 | 39,955 | Upgrade
|
| Operating Income | 28,775 | 24,653 | 25,307 | 21,439 | 22,431 | Upgrade
|
| Interest Expense | -39.42 | -40.78 | -21.32 | -8.84 | -38.46 | Upgrade
|
| Interest & Investment Income | 3,780 | 4,155 | 4,588 | 2,077 | 1,177 | Upgrade
|
| Currency Exchange Gain (Loss) | -308.18 | 2,006 | -117.74 | 205.38 | 662.9 | Upgrade
|
| Other Non Operating Income (Expenses) | 27.4 | -795.4 | -362.95 | -376.73 | -430.38 | Upgrade
|
| EBT Excluding Unusual Items | 32,234 | 29,978 | 29,393 | 23,335 | 23,801 | Upgrade
|
| Gain (Loss) on Sale of Investments | -31.81 | 251.15 | -2.76 | - | 48.48 | Upgrade
|
| Gain (Loss) on Sale of Assets | 59.1 | -17.17 | -3.7 | -6.05 | -3.23 | Upgrade
|
| Asset Writedown | -0.58 | -3.3 | -13.47 | -6.23 | -11.07 | Upgrade
|
| Pretax Income | 32,261 | 30,209 | 29,373 | 23,323 | 23,836 | Upgrade
|
| Income Tax Expense | 4,438 | 7,144 | 6,160 | 6,296 | 6,122 | Upgrade
|
| Net Income | 27,823 | 23,065 | 23,213 | 17,027 | 17,713 | Upgrade
|
| Net Income to Common | 27,823 | 23,065 | 23,213 | 17,027 | 17,713 | Upgrade
|
| Net Income Growth | 20.63% | -0.64% | 36.33% | -3.87% | -2.30% | Upgrade
|
| Shares Outstanding (Basic) | 16 | 16 | 16 | 16 | 16 | Upgrade
|
| Shares Outstanding (Diluted) | 16 | 16 | 16 | 16 | 16 | Upgrade
|
| Shares Change (YoY) | - | - | - | - | -0.95% | Upgrade
|
| EPS (Basic) | 1778.81 | 1474.61 | 1484.07 | 1088.60 | 1132.47 | Upgrade
|
| EPS (Diluted) | 1778.81 | 1474.61 | 1484.00 | 1088.50 | 1132.47 | Upgrade
|
| EPS Growth | 20.63% | -0.63% | 36.33% | -3.88% | -1.35% | Upgrade
|
| Free Cash Flow | 27,225 | 15,832 | 3,411 | 17,707 | 21,361 | Upgrade
|
| Free Cash Flow Per Share | 1740.59 | 1012.16 | 218.06 | 1132.04 | 1365.69 | Upgrade
|
| Dividend Per Share | 750.000 | 600.000 | 375.000 | 350.000 | 350.000 | Upgrade
|
| Dividend Growth | 25.00% | 60.00% | 7.14% | - | 7.69% | Upgrade
|
| Gross Margin | 65.36% | 62.20% | 67.33% | 68.66% | 70.95% | Upgrade
|
| Operating Margin | 21.77% | 20.71% | 26.06% | 25.21% | 25.51% | Upgrade
|
| Profit Margin | 21.05% | 19.38% | 23.91% | 20.02% | 20.14% | Upgrade
|
| Free Cash Flow Margin | 20.60% | 13.30% | 3.51% | 20.82% | 24.29% | Upgrade
|
| EBITDA | 31,930 | 27,803 | 26,980 | 23,055 | 23,931 | Upgrade
|
| EBITDA Margin | 24.16% | 23.36% | 27.79% | 27.11% | 27.22% | Upgrade
|
| D&A For EBITDA | 3,156 | 3,150 | 1,673 | 1,616 | 1,500 | Upgrade
|
| EBIT | 28,775 | 24,653 | 25,307 | 21,439 | 22,431 | Upgrade
|
| EBIT Margin | 21.77% | 20.71% | 26.06% | 25.21% | 25.51% | Upgrade
|
| Effective Tax Rate | 13.76% | 23.65% | 20.97% | 27.00% | 25.69% | Upgrade
|
| Advertising Expenses | 16,505 | 13,563 | 12,408 | 11,533 | 14,695 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.